# Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors

> **NCT07348042** · PHASE1 · RECRUITING · sponsor: **Xian-Jun Yu** · enrollment: 198 (estimated)

## Conditions studied

- Tumor, Solid

## Interventions

- **DRUG:** RGL-270 Injection
- **DRUG:** Adebelimab Injection

## Key facts

- **NCT ID:** NCT07348042
- **Lead sponsor:** Xian-Jun Yu
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-07
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07348042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07348042, "Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07348042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*